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Abstract. CD44-mediated cell adhesion to hyaluronate 
is controlled by mechanisms which are poorly under- 
stood. In the present work we examine the role of 
N-linked glycosylation and Ser-Gly motifs in regulating 
CD44-hyaluronate interaction. Our results show that 
treatment of a panel of human cell lines which constitu- 
tively express CD44 with the inhibitor of N-linked gly- 
cosylation tunicamycin results in the loss of attachment 
of these cells to hyaluronate-coated substrate. In con- 
trast, treatment of the same cells with deoxymannojiri- 
mycin, which inhibits the conversion of high mannose 
oligosaccharides to complex N-linked carbohydrates, 
results in either no change or an increase in CD44- 
mediated adhesion to hyaluronate, suggesting that 
complex N-linked oligosaccharides may not be re- 
quired for and may even inhibit CD44-HA interaction. 
Using human melanoma cells stably transfected with 
CD44 N-linked glycosylation site-specific mutants, we 
show that integrity of five potential N-linked glycosyla- 
tion sites within the hyaluronate recognition domain of 
CD44 is critical for hyaluronate binding. Mutation of 
any one of these potential N-linked glycosylation sites 
abrogates CD44-mediated melanoma cell attachment 
to hyaluronate-coated surfaces, suggesting that all five 
sites are necessary to maintain the HA-recognition do- 
main in the appropriate conformation. We also demon- 
strate that mutation of serine residues which constitute 
the four Ser-Gly motifs in the membrane proximal do- 
main, and provide potential sites for glycosaminoglycan 
side chain attachment, impairs hyaluronate binding. 
Taken together, these observations indicate that 
changes in glycosylation of CD44 can have profound ef- 
fects on its interaction with hyaluronic acid and suggest 
that glycosylation may provide an important regulatory 
mechanism of CD44 function. 
C 
D44 is a broadly distributed cell surface glycopro- 
tein  implicated  in  multiple  physiologic  cellular 
functions including cell-cell adhesion (Shimizu et 
al., 1989; St. John et al., 1990; Naujokas et al., 1993), lym- 
phocyte activation (Huet et al., 1989; Haynes et al., 1989; 
Denning et al., 1990; Naujokas et al., 1993), and cell-sub- 
strate interaction (Carter and Wayner, 1988; Aruffo et al., 
1990; Miyake et al., 1990; Stamenkovic et al., 1991; Tho- 
mas et al.,  1992).  Recent work has shown that CD44 can 
be  expressed  as  several  different isoforms, varying be- 
tween 85 and >200 kD, each of which may display some 
degree of functional uniqueness (Stamenkovic et al., 1989, 
1991; Brown et al., 1991; Gunthert et al., 1991; Jackson et 
al., 1992; Hoffman et al., 1991; Bartolazzi et al., 1994; Ben- 
nett et al., 1995). CD44 diversity is generated by differen- 
tial usage of 10 exons encoding a portion of the extracellu- 
lar domain (Screaton et al.,  1992)  and cell type-specific 
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glycosylation (Brown et al., 1991; Jalkanen and Jalkanen, 
1992). 
The most widely expressed isoform is the 85-90-kD gly- 
coprotein which represents  the  "standard" CD44  mole- 
cule, as it does not contain the products of differentially 
spliced exons (Stamenkovic et al., 1989; Goldstein et al., 
1989; Screaton et al., 1992). It is commonly referred to as 
CD44H and has been shown to be a major cell surface re- 
ceptor for hyaluronate (HA) 1 (Aruffo et al., 1990; Miyake 
et al., 1990). CD44H is the principal isoform found in he- 
matopoietic cells, fibroblasts, melanomas, and some epi- 
thelial cells (Stamenkovic et al., 1989, 1991; Hoffmann et 
al., 1991; Quackenbush et al., 1990), and most of its known 
functions are attributed to its ability to recognize HA on 
the surface of adjacent cells or bound to extracellular ma- 
trix (ECM) proteins.  Although all CD44 variants contain 
the HA-binding domain, their affinity for surface-bound 
hyaluronate is variable (Stamenkovic et al., 1991; Sy et al., 
1. Abbreviations used in this paper. ECM, extracellular matrix; CLP, carti- 
lage  link  protein;  GAG,  glycosaminoglycan; HA,  hyaluronate;  NGS, 
N-linked glycosylation site. 
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only weak attachment of cells to hyaluronate-coated sur- 
faces (Stamenkovic et al., 1991; Sy et al., 1991; Thomas et 
al., 1992).  These observations suggest that structural fea- 
tures and/or posttranslational modification of variant exon 
products may partially impair hyaluronate recognition by 
the HA-binding domain of CD44. 
The affinity for HA of CD44H itself varies according to 
the cell type in which it is expressed. Thus, normal lym- 
phocytes, as well as certain lymphoid cell lines which ex- 
press CD44H, do not bind soluble HA or adhere to HA- 
coated substrate  (Lesley and Hyman, 1992;  Hathcock et 
al., 1993; Liao et al., 1993; Murakami et al., 1993; Lesley et 
al., 1994). Similarly, several CD44H-positive nonlymphoid 
tumor cell lines fail to bind HA (Bartolazzi, A., and I. Sta- 
menkovic, unpublished observations). However, a specific 
anti-CD44 mAb (Lesley and Hyman, 1992; Lesley et al., 
1992),  phorbolesters  and  certain  cytokines  (Liao et  al., 
1993; Hathcock et al., 1993; Murakami et al., 1993) can in- 
duce  CD44-mediated  adhesion  to  HA  in  murine  lym- 
phoma cells and normal murine and human lymphocytes. 
The observed augmentation of adhesiveness to HA is not 
the consequence of an increased number of CD44 mole- 
cules on the cell surface, but rather appears to be due to a 
change in conformation and/or aggregation of CD44 which 
may be induced by antibody, cytokine, or mitogen-triggered 
posttranslational modifications. 
The extracellular region of CD44H is divided into two 
distinct  domains.  The NH2-terminal  135  residues  which 
form the HA-binding domain display a high degree of ho- 
mology to cartilage link protein (CLP)  and other ECM 
HA  receptors  (Stamenkovic et  al.,  1989).  This  domain 
contains  five  potential  N-linked  glycosylation sites  and 
one BXTB motif, where B is an arginine or lysine residue 
and X7 contains one basic but no acidic residues. Two ad- 
ditional overlapping BXTB motifs are found in close prox- 
imity to the  CLP homologous region, spanning residues 
150-162  (Yang et al., 1994).  BXTB motifs are required for 
HA binding and are present in most known cell surface 
and ECM HA receptors (Yang et al.,  1994). The mem- 
brane proximal domain contains four Ser-Gly motifs, which 
constitute the  minimal  sequence  for chondroitin sulfate 
(Mann et al., 1990), and possibly other glycosaminoglycan 
(GAG) attachment, as well as a  large number of serine 
and threonine residues which may provide sites for O-linked 
glycosylation.  Because  glycosylation may  contribute  to 
and be an integral part of the physiological activity of a 
glycoprotein, we performed site-directed mutagenesis  to 
address  the  role of the  potential N-linked  glycosylation 
sites and the Ser-Gly motifs in CD44H recognition of HA. 
We also used inhibitors of N-linked glycosylation to assess 
the importance of N-linked glycans in CD44H-HA inter- 
action.  Our  results  indicate  that  N-linked  glycosylation 
plays an important role in CD44H-mediated adhesion to 
HA-coated substrate, as does the integrity of the four ser- 
gly motifs. 
Materials and Methods 
Development of CD44 Mutants 
Fourteen CD44 site-directed mutants were prepared by encoding the de- 
sired mutation in overlapping oligonucleotide primers (Ho et aI.,  1989) 
and generating the mutations by PCR using CD44H cDNA in the CDM8 
expression vector (Thomas et al., 1992) as a template.  The mutants were 
generated in two groups. The first group was composed of mutations of 
the six potential N-linked glycosylation sites (NGS), five of which are lo- 
cated within the CLP homology domain. One set of mutants contained 
substitution of the Asn residue only, whereas a second set of mutants con- 
tained substitution of the corresponding Ser/Thr residue only (Table I). 
Mutants are labeled according to the specific mutation, N251, and accord- 
ing to the corresponding N-linked glycosylation site, which in this case 
would be NGS1. NGS are numbered 1-6 starting from the NH  2 terminus 
(Table I). 
Oligonucleotide primers used to derive each of the single NGS muta- 
tions were used to develop constructs containing mutations in multiple 
NGS. Two mutants containing substitution of Asn by Ile at NGS2-5 and of 
Ser/Thr by Ala at NGS3-5 were thus generated. 
The second group of mutants was composed of substitution of each of 
the four serine residues that constitute the Ser-Gly dipeptides located in 
the membrane proximal domain by alanine. Mutants were labeled accord- 
ing to the specific mutations, e.g., S180G, and the corresponding ser-gly 
dipeptide, e.g., Ser-Gly 1. Constructs were then made containing mutation 
of S180G/S190G  (Ser-Gly  1-2),  S180G/S190G/S231G  (Ser-Gly 1-3), and 
S180G/S190G/S231G/S258G (Ser-Gly 1-4). 
Standard forward and reverse primers corresponding to the 5' and 3' 
extremities of the coding sequence of CD44, containing, respectively, a 
HindlII and an XhoI restriction site, were used in alt PCR reactions, in 
combination with primers containing specific mutations. PCR conditions 
consisted of 30 cycles of 1 min at 94°C, 2 min at 58°C, and 3 min at 72°C.  5' 
and 3' amplified fragments were subjected to HindlIl/X and Xho I/X di- 
gestion, respectively, where X  represents the restriction site created for 
mutant generation, and ligated into HindlII-Xhol-cut CDM8 vector. In 
each case the creation of a new restriction site was performed by codon 
substitution that resulted in conservation of the wild-type residues or by 
generation of a  silent mutation.  All of the  mutants were  verified by 
dideoxy sequencing. PCR-generated errors were not observed. 
Cell Lines 
Development of stable CD44 transfectants in the human lymphoma Na- 
malwa (Stamenkovic et al., 1991) and the human melanoma MC (Thomas 
et al., 1992) have been described previously. Transfectants expressing the 
NGS CD44 mutants were labeled according to the specific mutant, e.g., 
MC44N25I,  or  according  to  the  position  of  the  mutated  NGS,  e.g., 
MC44NGS1.  Transfectants expressing composite mutants were  labeled 
according  to  the  mutated  NGSs,  including MC44NGS2-5  and  MC44- 
NGS3-5.  Similarly,  transfectants  expressing ser-gly  dipeptide  mutants 
were labeled according to the specific mutations within the transfected 
cDNA, e.g., MC44S180A/S190A or according to the position of the corre- 
sponding mutated Ser-Gly motifs, e.g., MC44Ser-GIy 1-2. MC44H and MC-T, 
respectively, express wild-type CD44H, and pSV2neo, the selection plas- 
mid containing the neomycin resistance gene. Transfections were  per- 
formed by electroporation (Gene Pulser, BioRad Labs, Hercules, CA) us- 
ing the same conditions as those previously described  (Thomas et  al., 
1992; Bartolazzi et al., 1994).  Clones were selected for G418 resistance in 
DMEM  (Irvine  Scientific,  Santa  Ana, CA)  supplemented with  2  mM 
glutamine (GIBCO BRL, Gaithersburg, MD), 10% FBS (Irvine), genta- 
mycin and 1 mg/ml G418. All transfectants were periodically tested for ex- 
pression of CD44 isoforms by indirect immunofluorescence. 
T24 bladder carcinoma cells were purchased from Amer. Type Culture 
Collection (Rockville, MD). The renal carcinoma cell line KJ29, the mela- 
nomas CT1 and FV1, and the breast carcinoma cells VR1 and MN were 
derived from primary tumors. 
Monoclonal Antibodies and Immunofluorescence 
The anti-human CD44 BRIC series of mAb, including BRIC 214, 222, 
235, and KZ1  (Antsee et al., 1991) were used in this study. Development 
of these antibodies has been described elsewhere (Antsee et al., 1991). 
Cells were  detached  from plates with EDTA,  washed, resuspended in 
PBS, and incubated with monoclonal antibodies (10-50 ixg/ml) for 45 rain 
at 4°C. Cells were then washed in PBS, incubated with fluorescein-labeled 
F(ab)2  fractions of goat anti-mouse affinity-purified antibody (Cappel, 
Malvern, PA) for 30 min at 4°C, washed, resuspended in PBS, and ana- 
lyzed on a fluorescence-activated analyzer (Becton-Dickinson, Mountain- 
view, CA). 
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Mutant  Glycosylation site  Antibody binding  of corresponding  MC melanoma  transfectants 
BRIC 214  BRIC 235  BRIC 222 
IF  IP  IF  IP  IF  IP 
CD44H  wt  + +  +  + +  +  + +  + 
N251  NGS 1  + +  +  + +  -  +  - 
T27A  NGS 1  + +  +  + +  -  +  - 
N57I  NGS2  + +  +  + +  -  + +  - 
N100I/N110I  NGS3-4  + +  +  + +  -  +  - 
T102A/S112A  NGS3-4  + +  +  + +  -  +  - 
N 1201  NGS5  + +  +  + +  -  +  - 
S 122A  NGS5  + +  +  + +  ND  +  biD 
N255I  NGS6  + +  +  + +  +  + +  ND 
N57I/N  100I/N110UN 120I  NGS2-5  + +  +  +  -  -  - 
T 102A/S 112A/S 122A  NGS3-5  + +  +  +  -  -  - 
S 180G/S 190G  Ser-Gly 1-2  + +  +  + +  +  + +  ND 
$231G  Ser-Gly 3  + +  +  + +  +  + +  ND 
S 180G/S 190G/$231G  Ser-Gly 1-3  + +  +  + +  +  + +  ND 
$258G  Ser-Gly 4  + +  +  + +  +  + +  ND 
S 180G/S 190G/$231G/S258G  Ser-Gly 1-4  + +  +  + +  +  + +  ND 
N2551dS258G  SerGIy4:NGS6  + +  +  + +  +  + +  ND 
CD44H N-linked glycosylation  site and Ser-Gly dipeptide motif  mutants.  Each specific mutation and the corresponding  glycosylafion  site are indicated. 
wt, wild type; IF, immunofluorescence;  ND, not done; + +, high antibody reactivity, (MFI:80-150); +, low antibody reactivity (MFI:20~I0); -, absence of detectable antibody 
binding by flow cytometry  (MFI< 10); IP, immunoprecipitation; +, effective immunoprecipitation  by indicated mAb; -, loss of ability to immunoprecipitate  CD44 mutants. 
Adhesion Assays 
96-well tissue culture plates were coated with 5 mg/ml hyaluronate, chon- 
droitin sulfate, or 10 i~g/ml fibronectin, collagen type I or collagen type VI 
or  heat  denatured  BSA  overnight  at  4°C,  and  nonspecific  sites  were 
blocked with 1 mg/ml BSA. The wells were washed with PBS and seeded 
with 51Cr-radiolabeled  MC transfectant cells  (105 cells/well)  in PBS.  Ad- 
hesion was allowed to proceed at 4°C for 30  min. The wells  were then 
washed three times with PBS, the adherent cells lysed with 1% SDS, and 
lysate radiolabel determined in a ~-counter. 
Development of CD44 Receptorglobulins 
The development of CD44-Ig fusion proteins (Receptorglobulins, Rg) has 
been reported earlier (Aruffo et al.,  1990). Receptorglobulins were pre- 
pared in COS cells and used to stain frozen rat kidney tissue sections be- 
fore and following treatment with N-glycanase as described (Aruffo et al., 
1990). 
Radiolabeling and Immunoprecipitation 
MC melanoma transfectants were washed and cultured in methionine-free 
medium (GIBCO BRL, Giathersburg, MD) supplemented with 10% dia- 
lyzed FBS for 2 h. Cells were then pulsed with 250 ixCi/ml of [35S]methio- 
nine (Amersham) for 12 h, washed in PBS, detached and lysed in a buffer 
containing 1% Triton X-100 (Sigma Chem. Co. St. Louis, MO),  10 Ixg/ml 
leupeptin (Sigma), 100 U/ml aprotinin (Sigma), and 10 IxM PMSF (Be- 
thesda Research Laboratories Inc., Bethesda, MD). After 1 h of lysis at 
4°C, nuclei were removed by centrifugation and lysates were precleared 
with protein A-Sepharose CLAB (Pharmacia, Uppsala, Sweden) coated 
with affinity-purified  rabbit anti-mouse IgG (Sigma). After preclearing, 
lysates were incubated with protein A-Sepharose CL4B coated with anti- 
CD44 mAb for 1 h at 4°C, the protein A-Sepharose beads washed, and 
the precipitates eluted by boiling.  Immunoprecipitates were analyzed by 
SDS/7.5%PAGE. The gels were fixed, dried, and subjected to autoradiog- 
raphy. 
For CD44Rg radiolabeling, COS cells transfected with CD44-Ig eDNA 
were incubated in methionine-free medium, as described above, 24 h after 
transfection, and pulsed with 250 ~Ci/ml of [35S]methionine for a duration 
of 18 h. Supernatants were then harvested and incubated with protein 
A-Sepharose beads for 2 h at 4°C. The beads were then washed and re- 
ceptorglobulins eluted as described (Bartolazzi et al., 1994) and analyzed 
by SDS-PAGE under reducing conditions. 
To determine CD44 shedding, equal numbers of transfectants were ra- 
diolabeled with [3SS]methionine as above. 72 h after radiolabeling, culture 
supernatants were harvested, precleared with protein A-Sepharose and 
shed CD44 immunoprecipitated as above. 
Inhibition of N-linked Glycosylation and Treatment 
with N-glycanase 
Tunicamycin  and  1-deoxymannojirimycin were  purchased  from Sigma 
Chem. Co.  To inhibit N-linked glycosylation,  3-10 p~g/ml of tunicamycin 
were added to the cell culture medium at the time of radiolabeling. Cells 
were incubated with tunicamycin for 12-18  h.  To inhibit processing of 
N-linked  glycans  to complex carbohydrate forms, cells  were incubated 
with 1-deoxymannojirimycin according to the protocol recommended by 
the vendor. To remove N-linked glycans  from mature CD44 receptors, 
protein A-Sepharose-bound CD44 immunoprecipitates were treated with 
10-20U of N-glycanase/sample (Boehringer Mannheim Corp., Indianapo- 
lis, IN) at 37°C at a pH of 7.2 overnight, according to the protocol recom- 
mended by the  vendor. The immunoprecipitates were then eluted  and 
subjected to SDS-PAGE as described above. Treatment of CD44Rg with 
N-glycanase was performed in a 100 I~l vol using 30 o~g of CD44 Rg and 
1 U of N-glycanase.  30 Ixg of N-glycanase-treated or -untreated CD44Rg 
were then used to stain frozen tissue sections.  Streptomyces hyaluronidase 
was used to pretreat frozen tissue sections as described previously (Aruffo 
et al., 1990). 
Results 
Development of CD44H N-linked Glycosylation 
Site Mutants 
To determine the role of N-linked glycosylation in CD44- 
mediated adhesion to hyaluronate, ten individual potential 
N-linked  glycosylation site  (NGS)-specific mutants  were 
developed (Fig. 1; Table I). The asparagine residue in each 
of the six potential NGS was substituted by an isoleucine 
(Table I). In addition, to ensure that any observed func- 
tional alteration associated with the mutations is due to a 
defect in glycosylation and not to the substitution  of the 
asparagine residue per se, the serine/threonine residues of 
a  subset of the potential NGS, at position  1,  3/4,  and 5, 
were substituted by an alanine  (Table I  and Fig.  1).  The 
mutants are labeled either according to the specific amino 
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L, leader peptide; CLP,  cartilage link protein homology domain; 
Trn, transmembrane domain; cyt, cytoplasmic domain. Amino ac- 
ids are denoted by their single letter code and numbered from the 
beginning of the leader peptide. Potential N-linked glycosylation 
sites (NGS) are numbered from the NH2 terminus. 
acid  substitution,  e.g.,  N25I,  or  according  to  the  corre- 
sponding N-linked glycosylation site, numbered 1-6 start- 
ing from the NH2 terminus, e.g., NGS1 (Table I). The ef- 
fect  of  deficient  glycosylation  on  multiple  NGS  was 
assessed by developing mutants containing substitution of 
Asn by lie on NGS2-5 and of Ser/Thr by Ala on NGS3-5. 
All of the mutants were tested for expression in COS cells 
by flow cytometry, using the anti-CD44 mAb BRIC 214. 
COS cells transfected with each of the mutants were rec- 
ognized  by BRIC214  mAb  (data  not  shown),  indicating 
that none of the mutations had resulted in the abrogation 
of CD44 transport to the cell surface. Each of the mutants 
was then stably expressed in the MC melanoma (Thomas 
et al., 1992;  Bartolazzi et al.,  1994).  Stable mutant CD44 
transfectants  are denoted  by the  prefix MC followed by 
the  identification  number  of  the  mutated  glycosylation 
site, e.g., MC44NGS1. 
Selection-medium resistant MC44NGS mutant transfec- 
tants were tested for CD44 expression by flow cytometry 
using  anti-CD44  BRIC214  mAb,  and  transfectants  ex- 
pressing comparable levels of CD44NGS mutants selected 
for further study. Immunoprecipitation of the CD44NGS 
mutants  from  lysates  of  radiolabeled  transfectants  re- 
vealed unequal glycan content of the six potential N-linked 
glycosylation sites (Fig. 2). Mutation of the Asn residue in 
NGS 1, 2, and 6 resulted in a minimal shift in the molecu- 
lar mass (Mr) of CD44 (Fig. 2 and data not shown). Simul- 
taneous mutation of Ash in NGS 3 and 4 resulted in a sig- 
nificant  decrease  in  molecular mass, of ~5-8  kD, while 
immunoprecipitation of CD44 containing Asn substitution 
Figure 2.  Immunoprecipita- 
tion of CD44HNGS mutants 
from  35S-radiolabeled  MC 
transfectant  lysates. Immuno- 
precipitations were performed 
with the BRIC214 mAb from 
radiolabeled lysates of trans- 
fectants  expressing  mutants 
containing  Ash  substitutions 
at potential NGS. Lysates were 
from lane A,  MC44HNGS1; 
lane B, MC44HNGS2; lane C, 
MC44HNGS3-4;  lane  D, 
MC44HNGS5;  lane  E, 
MC44HNGS2-5;  lane  F, 
MC44H;  lane  G, MCA4H, immunoprecipitated with  unrelated 
isotype-matched mAb. Molecular mass(kD) is indicated. 
by Ile in NGS5 revealed a greater Mr reduction, of ~15 kD 
(Fig. 2). A  combination of Asn mutations in NGS2-5 (Fig. 
2) and of Ser/Thr mutations in NGS3-5 (data not shown) 
resulted in the expression of a  60-62-kD CD44 polypep- 
tide, indicating that most of the N-linked glycosylation of 
CD44H expressed in MC melanoma cells requires the in- 
tegrity of NGS 3/4-5. 
Substitution of serine/threonine residues of NGS 1, 3/4, 
and 5 by alanine (Table I) resulted in a shift in molecular 
weight comparable to that observed upon mutation of the 
corresponding Asn residues (data not shown). 
NGS Mutations Induce Alterations in Antibody-binding 
Epitopes of CD44 
All of the NGS mutants expressed in MC cells were tested 
for recognition by four anti-CD44 mAb, BRIC214, BRIC- 
222, BRIC235, and KZ1 (Antsee et ah,  1991).  BRIC214, 
BRIC222, and KZI are noncross-blocking antibodies (Ant- 
see et al.,  1991)  and have been proposed to define three 
separate  epitope  groups.  BRIC214  and  BRIC235  cross- 
block each other, and belong to the same antibody group 
although they may recognize distinct epitopes (Antsee et 
al.,  1991).  All  of the  individual  as well as the composite 
NGS mutants expressed in MC melanoma cells were rec- 
ognized by the  BRIC 214  and  KZ1  mAbs  (Table  I  and 
data not shown). Moreover, single NGS mutant and wild- 
type CD44H transfectants displayed comparable staining 
intensity with the two mAb in flow cytometry assays (Ta- 
ble  I  and  data not  shown),  and  all  of the  NGS mutants 
could be immunoprecipitated with BRIC214  (Fig.  1  and 
Table I). The BRIC 222 mAb bound MC transfectants ex- 
pressing individual  NGS mutants at positions  1 to 5  less 
strongly than MC44H cells and failed to stain MC trans- 
fectants expressing NGS2-5  and  NGS3-5 mutants (Table 
I). The anti-CD44 mAb BRIC 235, which immunoprecipi- 
tates  CD44H  and  blocks  CD44-HA  interaction  (this 
study), was observed to bind MC44H and all of the indi- 
vidual NGS mutant transfectants comparably in flow cy- 
tometry assays. However, BRIC235 failed to immunopre- 
cipitate CD44NGS mutants, with the exception of NGS6, 
from corresponding lysates (Table I). 
NGS Mutations within the HA-binding Domain 
Abrogate CD44-mediated Cell Attachment to HA 
To address the possible functional effects of NGS muta- 
tions, MC44NGS mutant transfectants were tested for ad- 
hesion to HA-coated plates. Although, CD44H expression 
promoted MC transfectant attachment to HA, none of the 
CD44NGS  mutant  transfectants,  with  the  exception  of 
MC44NGS  6,  displayed significant CD44H-mediated  ad- 
hesion to HA-coated substrate (Fig. 3 A). Binding of NGS 
mutant  transfectants  to  fibronectin,  collagen  I,  laminin, 
collagen  VI,  and  chondroitin  and  heparan  sulfate  was 
comparable to that of wild-type CD44H transfectants (Fig. 
3 B and data not shown). 
Different Types of  lnhibitors of  N-linked 
Glycosylation  Can Abrogate, Maintain, or Enhance 
CD44-mediated Adhesion to HA 
Treatment of MC44H transfectants with tunicamycin ab- 
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mutant transfectants  to (A) HA-coated plates and (B) to plates 
coated with a variety of ECM substrates, including chondroitin 
sulfate (CS), heparan sulfate (HS), collagen type I  (Coil), col- 
lagen type VI  (ColVI),  laminin (LM), and  hyaluronate (HA). 
NGS mutants are indicated. MCT are MC cells transfected with 
pSV2Neo only. All experiments were performed in sextuplicate 
and adhesion is expressed as the percentage of cells which adhered 
to each substrate following the 30-min incubation period at 4°C. 
rogated their adhesion to HA  (Fig. 4 A)  without  signifi- 
cantly affecting the level of CD44 cell surface expression 
(data  not  shown).  In  addition, tunicamycin treatment  of 
the  human  lymphoma Namalwa  CD44H  transfectants  as 
well  as  several  tumor  cell lines  which  constitutively ex- 
press CD44H and bind HA in a CD44-dependent manner, 
resulted in decreased adhesion to HA-coated plates (Fig. 4 
B).  To  determine  whether  complex  N-linked  glycosyl 
chains may participate in CD44-mediated MC melanoma 
adhesion to HA, MC44H  transfectants were treated with 
1-deoxymannojirimycin which  specifically inhibits  mam- 
malian Golgi et-mannosidase I  activity and the conversion 
of high mannose to complex oligosaccharides (Roth, 1987). 
As a result, cell surface and secreted glycoproteins are syn- 
thesized which  contain  Man9GlcNAc2, but  typically lack 
N-linked galactose, fucose, and sialic acid residues. Deoxy- 
Figure 4.  Effect of tunicamycin and  1-deoxymannojirimycin on 
CD44H-mediated cell attachment  to HA-coated substrate. (A) 
Adhesion of 51Cr-radiolabeled native, tunicamycin, and deoxy- 
mannojirimycin-treated  MC-T (MC cells transfected with pSV2Neo 
only) and MC44H cells to HA in the presence or absence of the 
blocking BRIC235  mAb.  The  percentage  of cells adhering to 
HA-coated plates after a 30-min incubation at 4°C is indicated. 
(B)  Adhesion to  HA-coated plates of a  panel of 51Cr-radiola- 
beled  native,  tunicamycin,  and  deoxymannojirimycin-treated 
cells which express CD44H. The cell lines used were K J29, hu- 
man renal carcinoma; Namalwa 44H, human lymphoma Namalwa, 
stably transfected with CD44H; T24,  human bladder carcinoma; 
FV and CT, human melanomas derived from two different pa- 
tients; VR and MN, human breast carcinomas derived from two 
different patients. Adhesion assays were performed as in A. All 
adhesion assays were done in sextuplicate. (C) Immunoprecipita- 
tion of CD44,  using BRIC214  mAb, from  lysates of 35S-radio- 
labeled native and deoxymannojirimycin-treated  MC44H and T24 
cells. Lysates were  from  lane A, untreated  T24  cells; lane B, 
deoxymannojirimycin-treated  T24 cells; lane C, untreated MC44H 
cells; lane D, deoxymannojirimycin-treated  MC44H cells. 
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tion in the molecular mass of CD44H (Fig. 4  C) but was 
accompanied by an  augmentation in  CD44-mediated at- 
tachment of MC cells to HA-coated surfaces (Fig. 4 A). 
The observed increase in HA binding was blocked by anti- 
CD44  mAb  BRIC235  (Fig.  4  A).  Deoxymannojirimycin 
treatment of the other cell lines revealed either no signifi- 
cant change or an increase in attachment to HA (Fig. 4 B). 
It is noteworthy, however, that two breast carcinoma cell 
lines failed to bind HA despite expressing CD44H. Tuni- 
camycin  and  deoxymannojirimycin  treatment  of  these 
cells failed to induce CD44-mediated adhesion (Fig. 4 B). 
Deglycosylation of Soluble CD44-Ig Fusion Protein 
Reduces Its Ability to Bind HA in Mammalian Tissues 
To provide further evidence that N-linked glycosylation of 
CD44 plays a role in regulating its ability to interact with 
HA, CD44-Ig fusion protein (CD44Rg) produced in COS 
cells  was  subjected  to  N-glycanase  treatment  and  com- 
pared to untreated CD44Rg for staining rat kidney papilla 
which is rich in HA. Treatment of CD44Rg with N-glyca- 
nase  abrogated  its  ability to  bind  tissue-associated  HA 
(Fig.  5,  A-E)  and  caused  a  significant  reduction  in  its 
molecular mass  (Fig. 5 F). Pretreatment of frozen tissue 
sections  with  hyaluronidase  abolished  CD44Rg  binding 
(Fig. 5 a). 
Development of CD44H Ser-Giy Dipeptide Mutants 
CD44H contains four Ser-Gly dipeptides in the membrane 
proximal domain,  which  provide potential sites  for gly- 
cosaminoglycan side chain attachment (Mann et al., 1990). 
To determine whether any of these sites is substituted in 
GAG side chains in MC cells, and to assess the potential 
role of these sites in  regulating CD44H-HA interaction, 
the serine residue within each Ser-Gly motif was mutated 
to  a  glycine  (Fig.  6).  CD44  cDNA  mutants  encoding 
S180G/S190G  (Ser-Glyl 2),  $231G  (Ser-Gly 3),  S180G/ 
S190G/S231G  (Ser-Gly  1-3),  $258G  (Ser-Gly  4),  and 
S180SG/S190G/S231G/S258G  (Ser-Gly  1-4)  were  intro- 
duced into MC cells by electroporation and transfectants 
expressing comparable levels of CD44Ser-GIy mutants on 
the cell surface were selected for further analysis (Table I). 
Immunoprecipitation of each of the CD44Ser-Gly mutants 
from  lysates  of radiolabeled  MC  transfectants  revealed 
that mutation of the serine residues had not resulted in a 
significant reduction of the molecular mass of CD44 (Fig. 
7). This observation suggests that in MC melanoma cells 
these sites are not occupied by large GAG side chains, al- 
though it does not exclude the possibility that they may 
contain O-linked monosaccharides. Surprisingly, the mo- 
lecular weight of Ser-Gly 4  and Ser-Gly 1-4 mutants was 
slightly increased with respect to that of wild-type CD44H 
(Fig. 7). 
Ser-Gly Mutations Reduce CD44-mediated 
Adhesion to HA 
CD44 Ser-Gly mutant transfectants were tested for adhe- 
sion to HA-coated plates. In comparison to CD44H trans- 
fectants,  adhesion  of CD44Ser-Gly mutant  transfectants 
was found to be decreased by ~50% (Fig. 8). No significant 
difference in adhesiveness among the different CD44Ser- 
Gly mutant transfectants was observed, indicating that the 
effect of substituting  one serine residue on CD44-medi- 
ated adhesion to HA was comparable to that of mutating 
all four Ser-Gly-associated serines. Similar to CD44NGS 
mutant transfectants, MC cells expressing Ser-Gly dipep- 
tide mutants were not observed to display adhesiveness to 
collagens,  laminin  or  chondroitin,  and  heparan  sulfate 
(data not shown). 
Figure  5.  Immunofluorescence  (A,  C-E) 
and phase contrast (B) micrographs  of rat 
renal papilla tissue sections. Untreated fro- 
zen sections were stained with (A) CD44Rg, 
(C)  CD44Rg  pretreated with  N-glycanase 
and  (E)  CD8Rg  control.  Hyaluronidase- 
treated  tissue  stained  with  CD44Rg  is 
shown in D. (F) Immunoprecipitation  of un- 
treated  (lane  A)  and  N-glycanase-treated 
(lane B) CD44Rg. 
Figure 6. Schematic representation of Ser-Gly and NGS6 muta- 
tions. Amino acids are denoted by their single letter code and 
numbered from the beginning of the leader peptide (L). 
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tants were immunoprecipitated from 35S-radiolabeled transfec- 
tant lysates and corresponding 24 h cell culture supernatants with 
BRIC 214 mAb. Immunoprecipitates were, respectively, from ly- 
sates and supernatants of lanes 1 and 2, MC44H; lanes 3 and 4, 
MC44Ser-Gly 1-2; lanes 5 and 6, MC44Ser-Gly 1-4; lanes 7 and 8, 
MC44Ser-GIy 1-3; lanes 9 and 10, MC44Ser-Gly 4; lanes 11 and 
12,  MC44Ser-Gly  4/N258I. Molecular  mass markers  are  indi- 
cated. 
Mutation of 258S Induces Glycosylation 
of 255N (NGS6) and Enhances Spontaneous 
Shedding of CD44 
In an effort to explain the increase in molecular mass after 
substitution of 258Ser by Gly, we addressed the possibility 
that the potential N-linked glycosylation site immediately 
upstream of 258Ser (NGS6) (Fig. 6) might become glyco- 
sylated as a result of the 258Ser mutation. Substitution of 
255Asn by Ile in the Ser-Gly 4 mutant (N255I/S258G) re- 
sulted in the restoration of the molecular mass of CD44Ser- 
Gly 4 to the level of that of wild-type CD44H (Fig. 7, lane 
11). To provide further evidence that the increase in mo- 
lecular mass of Ser-Gly 4 and Ser-Gly 1-4 mutants was due 
to  N-linked  glycosylation,  CD44H,  CD44Ser-Gly 4,  and 
CD44Ser-Gly  1-4  immunoprecipitates  were  treated  with 
N-glycanase and the corresponding molecular masses com- 
pared by SDS-PAGE. Migration of the different N-glyca- 
nase-treated immunoprecipitates was observed to be simi- 
lar (Fig. 9), supporting the notion that a mutation of 258Ser 
resulted in glycosylation of NGS6. 
CD44H as well as other CD44 isoforms are  spontane- 
ously shed from various cell types (Bartolazzi et al., 1994, 
1995).  Spontaneous shedding of CD44 was observed to be 
significantly increased in MC44S258G cells with respect to 
MC44H transfectants (Fig. 7, lane 10). However, mutation 
of N255I in the Ser-Gly 4 mutant restored shedding to a 
level similar to that observed in MC44H cells (Fig. 7, lane 
12). Mutation of Ser-Gly 1-4 resulted in abrogation of de- 
tectable  CD44  shedding  from  MC  transfectants  (Fig.  7, 
lane 6). 
Discussion 
The structural features of CD44 required for HA binding 
Figure 8. Adhesion of 51Cr-radiolabeled MC44Ser-Gly  transfec- 
tants  to  HA-coated plates.  MCA4Ser-Gly mutant  transfectants 
are indicated. MCT represent MC cells transfected with pSV2Neo 
only. All experiments were done in sextuplicate  and adhesion is 
expressed as the percentage of ceils adhering to HA-coated plas- 
tic after a 30-min incubation  at 4°C. 
and regulation of CD44-mediated cell adhesion to HA are 
still poorly understood. Recent work has shown that muta- 
tion of a  single arginine residue  (41Arg) within the carti- 
lage  link  protein  homology domain  of CD44  abrogates 
binding to HA (Peach et al.,  1993).  A  subsequent,  more 
extensive study on HA-binding domains showed that  all 
known cell surface and ECM HA receptors contain one or 
several BXTB motifs which  are required  for HA binding 
(Yang et al., 1994).  Although the discovery of these HA- 
binding motifs is a  major step toward understanding  the 
mechanism of interaction between HA and HA receptors, 
the observation that several cell types which express CD44H 
do not bind HA unless they are triggered by specific stim- 
uli suggests that additional structural features of HA-bind- 
ing proteins may play a role in regulating receptor affinity 
for  HA.  The  results  of  the  present  study  indicate  that 
Figure 9.  N-glycanase  treatment of CD44H and  CD44Ser-Giy 
mutants.  Immunoprecipitation of CD44H and CD44Ser-Gly mu- 
tants from lysates of 35S-radiolabeled MC transfectants was per- 
formed using the BRIC214 mAb. Immunoprecipitates bound to 
protein A-Sepharose beads were treated with  N-glycanase  be- 
fore being eluted  and  subjected  to  SDS-PAGE. Lysates were 
from  MC  transfectants  expressing:  lane  A,  CD44H;  lane  B, 
CD44Ser-Gly  1-2; lane  C, CD44Ser-GIy  1-3; lane D, CD44Ser- 
Gly 4; lane E, CD44Ser-Gly  1-4; lane F, CD44Ser-Gly 3; lane G, 
CD44H, immunoprecipitated  with an isotype-matched mouse IgG. 
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CD44 N-linked glycosylation, and to a lesser extent to the 
integrity of Ser-Gly motifs. 
Role of N-linked Glycosylation in 
CD44H-HA Interaction 
N-linked oligosaccharides are thought to play an impor- 
tant role in the processing and physiologic function of gly- 
coproteins  (Olson  and  Lane,  1987;  Rademacher  et  al., 
1988; Yang et al., 1993), based on observations that inhibi- 
tion of N-linked glycosylation can result in glycoprotein 
misfolding, abrogation of cell surface expression or loss of 
function. Treatment of MC transfectants as well as a num- 
ber of cell lines which constitutively express CD44H with 
tunicamycin, resulted in abrogation of CD44-mediated at- 
tachment of the cells to HA-coated substrate which was 
not due to the loss of CD44 expression. Although these 
observations suggest that N-linked glycosylation of CD44 
is important in CD44-mediated cell adhesion to HA, non- 
specific glycosylation inhibitors, such as tunicamycin, block 
N-linked oligosaccharide addition to a multitude of cellu- 
lar proteins. As a result, the abundance of misfolded pro- 
teins may obscure the normal fate and functional changes 
of  any  individual  deglycosylated protein.  We  therefore 
used site-directed mutagenesis to develop single and mul- 
tiple N-linked glycosylation site mutants  in CD44H  and 
address the effect of each mutant on the expression and 
HA-binding potential of CD44H in MC melanoma cells. A 
similar approach has shown that single NGS mutations al- 
ter expression, processing, cleavage as well as ligand-bind- 
ing affinity of the transferrin receptor (Yang et al., 1993). 
Our results demonstrate that processing and transport of 
CD44H  to the  cell surface can occur in  the  absence  of 
most N-linked glycosyl chains, since all of the mutants de- 
veloped in this study could be expressed on the cell surface 
and were found to retain at least some epitopes recognized 
by the anti-CD44 mAb panel. However, changes in bind- 
ing affinity of some of the antibodies, reflected by a reduc- 
tion in staining or loss of the ability to immunoprecipitate 
CD44 mutants, suggest that mutation of each of the CLP- 
homology domain NGS may result in functionally signifi- 
cant conformational changes, sufficient to abrogate ligand 
binding. These results have at least three possible, nonmu- 
tually exclusive explanations. The first is that N-linked gly- 
cans themselves are involved in CD44-mediated adhesion, 
either by facilitating aggregation of CD44 molecules or by 
providing the appropriate conformation to the HA-bind- 
ing domain. Such an explanation is not without precedent, 
since recent work has shown that  a  single N-linked oli- 
gosaccharide in the extracellular domain of CD2 provides 
the  configuration  necessary  for  CD2-CD58  interaction 
(Wyss et al., 1995), and that a single N-linked glycan regu- 
lates interactions between CD22  and its ligands  (I.  Sta- 
menkovic, unpublished). The second possible explanation 
is that conformational alterations induced by mutation of 
asparagine and serine/threonine residues which constitute 
the potential N-linked glycan sites may participate in the 
loss of CD44-mediated cell adhesion to HA. It would im- 
ply that the capability of CD44 to mediate cell adhesion to 
HA is highly sensitive to the mutation of multiple residues 
within the CLP domain which are unrelated to the BX7B 
motifs. Finally, conformational changes due to mutation of 
one N-linked glycosylation site may render other sites in- 
accessible to appropriate glycosyltransferases. Thus, it is 
possible that the 15-kD reduction in molecular mass after 
mutation  of NGS5  is  not  due  to  the  loss  of glycans at 
NGS5 only but may reflect impaired glycosylation of other 
potential sites as well. Additional work will be necessary 
to resolve the mechanism by which each NGS mutation in- 
hibits CD44-mediated cell adhesion to HA. However, the 
observation that treatment of CD44Rg with N-glycanase 
results in almost complete abrogation of its ability to bind 
HA in tissues provides support to the notion that N-linked 
glycosyl chains  play  an  active role in  the  regulation  of 
CD44-mediated adhesion to HA. 
Treatment of MC44H  cells with  1-deoxymannojirimy- 
cin, which  inhibits  the  conversion of high  mannose  oli- 
gosaccharides to complex carbohydrates, enhanced adhe- 
sion to HA. Inhibition of complex N-linked oligosaccharide 
synthesis in Namalwa CD44H transfectants, T24 and FV1 
cells  all of which display CD44-mediated  attachment to 
HA-coated plates, also resulted in a significant increase in 
CD44-dependent adhesion to HA-coated substrate. These 
observations suggest that high mannose N-linked glycans 
may help maintain the HA-binding domain in its appropri- 
ate conformation whereas complex N-linked oligosaccha- 
rides may inhibit CD44-HA interaction. It is conceivable 
that the structure and charge of complex galactose, fucose, 
and sialic acid-containing oligosaccharides synthesized by 
some cells may reduce CD44-HA-binding affinity. 
Importantly, our  results  suggest  that  the  mechanisms 
which regulate the adhesive properties of CD44H may not 
be the same in all cell types. In some cells, which bind HA, 
deoxymannojirimycin treatment failed to augment CD44- 
mediated adhesion. In two breast carcinoma cell lines, ex- 
pression of CD44H failed to promote attachment to HA, 
and treatment of these cells with tunicamycin and deoxy- 
mannojirimycin  did  not  induce  adhesion.  It  therefore 
seems  likely  that  glycosylation  may  promote  different 
CD44-associated adhesive properties in different cell types, 
while in some cells factors other than glycosylation may be 
the primary regulators of CD44-mediated attachment to HA. 
Recently, two independent studies (Katoh et al.,  1995; 
Lesley et al., 1995) showed that glycosylation is involved in 
the regulation of CD44-HA interaction. Unlike the obser- 
vations reported here, prolonged tunicamycin treatment 
(2-3 d) of some cell  lines changed the endogenous CD44 
HA-binding function from inactive to active (Lesley et al., 
1995).  The discrepancy between these  observations  and 
ours is most likely due to the different properties of the 
cell lines tested, and possibly to the different duration of 
cell exposure to tunicamycin which may have caused addi- 
tional posttranslational  changes.  Thus,  our  observations 
do not necessarily contradict the results reported by Les- 
ley et al. (1995) and Katoh et al. (1995) but rather under- 
score the complex nature of the regulation of CD44-depen- 
dent adhesion. 
Effects of Ser-Gly Motif Mutation on the Structure and 
Function of CD44H 
To determine the role of potential glycosylation sites distal 
to the HA-binding domain in the regulation of ligand rec- 
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brane proximal domain of CD44H individually or in com- 
bination. Ser-Gly dipeptides are potential sites for GAG 
side chain attachment (Mann et al., 1990). Although high 
Mr GAG side chains have recently been shown to be asso- 
ciated with expression of CD44 variant exon 3 (Bennett et 
al.,  1995;  Bartolazzi et  al.,  1995), there  is  evidence that 
CD44H can behave as a facultative proteoglycan, bearing 
GAG chains in some cell types but not in others (Stamen- 
kovic et al., 1989; Stamenkovic et al.,  1991; Jalkanen and 
Jalkanen, 1992; Jackson et aL, 1995).  Mutation of all four 
Ser-Gly motifs failed to produce a significant reduction in 
Mr which would result from abrogation of GAG side-chain 
attachment, suggesting that in MC cells, CD44 does not 
contain Ser-Gly-associated high molecular weight GAGs. 
However, this observation does not exclude the possibility 
that these serine residues may be sites of attachment of 
O-linked glycosyl chains. Because O-linked carbohydrates 
typically consist  of oligo- or even monosaccharides,  re- 
moval of a few O-linked glycosylation sites would not be 
expected to detectably alter the Mr of an 85-kD glycopro- 
tein on a standard SDS gel. 
Ser-Gly mutations in CD44H highlighted the sensitivity 
of HA binding to substitution of amino acids distal to the 
HA-recognition domain.  Each  of the  Ser-Gly mutations 
reduced  CD44-mediated  binding  to  HA  of  the  corre- 
sponding transfectants by N50% with respect to wild-type 
CD44H-expressing  counterparts.  The  effect of  a  single 
Ser-Gly mutation, however, was the same as that of muta- 
tion of all  four motifs. The reduction in  HA  binding is 
likely to be due to a conformational change of CD44, but 
whether such  a  change is due to the substitution of the 
serine residues themselves or to the loss of putative oli- 
gosaccharides which they may carry remains to be deter- 
mined. 
Two unexpected observations were made using Ser-Gly 
dipeptide  mutants.  The  first  was  that  mutation  of the 
serine residue constituting the fourth Ser-Gly dipeptide, 
immediately downstream of NGS6 resulted in glycosyla- 
tion of NGS6 reflected by an increase in Mr which could 
be restored to the wild-type level by mutation of the NGS6 
asparagine  residue.  Migration  of immunoprecipitates  of 
N-glycanase-treated CD44 from MC44H  and MC44SG4 
lysates  on  SDS-PAGE  was  comparable,  giving  further 
support to the notion that mutation of Ser-Gly 4 results in 
glycosylation of NGS6. This finding suggests that 258Ser 
introduces a structural feature which blocks N-linked gly- 
cosylation on 255Ash. 
The second unexpected event resulting from the muta- 
tion of Ser-Gly 4 was a significant increase in spontaneous 
shedding of CD44. The mechanisms which regulate CD44 
shedding  are unknown,  although proteolytic cleavage of 
the extracellular domain appears likely (Bazil and Hor- 
eijsi, 1991; Bartolazzi et al.,  1994,  1995).  We have shown 
recently that spontaneous shedding of CD44 splice vari- 
ants expressed in MC melanoma (Bartolazzi et al.,  1994) 
and in Namalwa lymphoma cells (Bartolazzi et al., 1995) is 
significantly  greater  than  that  of  CD44H.  Mutation  of 
258Ser enhanced CD44 release whereas simultaneous mu- 
tation of 255Asn and 258Ser restored shedding to baseline 
levels.  These  observations  suggest  that  glycosylation of 
NGS6 as a result of mutation of 258Ser altered local CD44 
conformation, rendering the cleavage site more accessible 
to  the  putative  protease.  Analogous  observations  have 
been made on N-glycosylation--dependent proteolytic cleav- 
age of the transferrin receptor (Hoe and Hunt, 1992). In- 
terestingly,  mutation  of all  four  Ser-Gly dipeptides  re- 
sulted in abrogation of detectable shedding suggesting that 
the  structural  change  induced  by the  substitution  of all 
four serine residues may conceal or alter the proteolytic 
cleavage site. 
Taken together, our results show that CD44H-mediated 
cell adhesion to HA-coated surfaces and tissue-bound HA 
is highly sensitive to structural changes in both the HA- 
binding  and  the  membrane-proximal  domain.  N-linked 
glycosylation is shown to be involved in the regulation of 
CD44-mediated adhesion to HA, but it is not the only reg- 
ulator, since we have shown that some cell lines which ex- 
press CD44H fail to adhere to HA irrespective of whether 
they are treated with various inhibitors of glycosylation or 
not. Furthermore, glycosylation-associated regulatory mech- 
anisms of CD44-HA interaction appear to be both com- 
plex and cell type-specific. Elucidation of the composition 
of N-linked carbohydrates capable of inhibiting or enhanc- 
ing CD44-HA interaction will be of interest and may help 
elucidate, in part, the selectivity with which CD44H medi- 
ates adhesion to HA. 
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